EUVIMEDEUVIMED entdecken
Crossref

Treatment Outcomes with Empirical Clarithromycin-Based Triple Therapy for Helicobacter pylori in Zambia, Sub-Saharan Africa

Ibrahim Patel, Lailai Kinkungwe, Shabir Lakhi, Violet Kayamba

Digestive Diseases · 22.06.2026 · 1-8

DOI: 10.1159/000552612 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Digestive Diseases, online erschienen am 22.06.2026. Verfasst von Ibrahim Patel und 3 weiteren Autor:innen. Beteiligte Einrichtung: University of Zambia School of Medicine, Lusaka, Zambia. Hauptthemen laut MEDLINE: Clarithromycin, Helicobacter pylori, Helicobacter Infections, Anti-Bacterial Agents. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Helicobacter pylori (H. pylori) infection is highly prevalent in Zambia, with an estimated population prevalence of 79%. However, data on eradication treatment outcomes in routine clinical practice are lacking.

Methods

We conducted a single-arm cohort study in Lusaka, Zambia, to evaluate the effectiveness of empirical H. pylori eradication therapy using stool antigen testing (SAT). Symptomatic patients with confirmed H. pylori infection were treated empirically with clarithromycin-, tinidazole-, and omeprazole-based regimens. Eradication was assessed using SAT at least 4 weeks after completion of therapy. Demographic and clinical factors associated with treatment outcomes were analysed using multivariate logistic regression in Stata version 15.

Results

Of 331 patients tested, 216 (65%) were positive for H. pylori infection. Post-treatment SAT results were available for 139 (64%) patients, of whom 93 (67%) were female. The median age was 43 years (interquartile range: 36–54). Overall, eradication was achieved in 85 patients, yielding a treatment success rate of 61%. Multivariate analysis demonstrated that a history of prior eradication attempts (odds ratio [OR]: 0.20, 95% confidence interval [CI]: 0.04–0.60) was independently associated with treatment failure. In contrast, the occurrence of dysgeusia during therapy (OR: 3.20, 95% CI: 1.20–8.70) and prior proton pump inhibitor use (OR: 5.30, 95% CI: 1.40–19.80) were associated with higher odds of eradication.

Conclusion

The effectiveness of empirical clarithromycin-based therapy for H. pylori infection in Zambia is suboptimal and falls below internationally recommended targets. These findings underscore the need to reassess empirical treatment strategies, particularly among patients with previous eradication attempts, and highlight the importance of locally informed antibiotic selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClarithromycinHelicobacter pyloriHelicobacter InfectionsAnti-Bacterial AgentsHumansFemaleZambiaMaleAdultTreatment OutcomeMiddle AgedDrug Therapy, CombinationTinidazole

Stichwörter der Autor:innen

Empirical treatmentEradication successHelicobacter pyloriStool antigen testZambia

Substanzen

ClarithromycinAnti-Bacterial AgentsTinidazole

Autor:innen und Institutionen

  • University of Zambia School of Medicine, Lusaka, Zambia.
  • University Teaching Hospital, Lusaka, Zambia.
  • Tropical Gastroenterology and Nutrition Group, Lusaka, Zambia.
  • University of Zambia School of Medicine, Lusaka, Zambia, viojole@yahoo.com.
  • Tropical Gastroenterology and Nutrition Group, Lusaka, Zambia, viojole@yahoo.com.

Zitieren

APA

Patel, I., Kinkungwe, L., Lakhi, S., & Kayamba, V. (2026). Treatment Outcomes with Empirical Clarithromycin-Based Triple Therapy for Helicobacter pylori in Zambia, Sub-Saharan Africa. Digestive Diseases, 1-8. https://doi.org/10.1159/000552612

Vancouver

Patel I, Kinkungwe L, Lakhi S, Kayamba V. Treatment Outcomes with Empirical Clarithromycin-Based Triple Therapy for Helicobacter pylori in Zambia, Sub-Saharan Africa. Digestive Diseases. 2026:1-8. doi:10.1159/000552612

BibTeX
@article{Patel2026,
  author = {Patel, Ibrahim and Kinkungwe, Lailai and Lakhi, Shabir and Kayamba, Violet},
  title = {Treatment Outcomes with Empirical Clarithromycin-Based Triple Therapy for Helicobacter pylori in Zambia, Sub-Saharan Africa},
  journal = {Digestive Diseases},
  year = {2026},
  pages = {1--8},
  doi = {10.1159/000552612}
}
Kostenlos starten →